2026 Home Health Valuation Multiples Report (US Market)
Audience: This report is written for home health owners evaluating a sale and buyers evaluating acquisitions. It focuses on EBITDA multiples, with a short explanation of how revenue ties into valuation.
Quick links:
Hospice M&A |
Home Health M&A |
How to Value Your Healthcare Business |
How to Sell a Hospice or Home Health Agency |
Join Our Buyer Network
Key takeaway: In 2026, strong agencies are still earning strong multiples. The multiple you achieve is driven by defensible EBITDA, compliance readiness, quality metrics, staffing stability, and scale.
1) Market Snapshot: What is Driving Home Health Valuations in 2026?
- Deal momentum is returning. Buyers are active again, but diligence is tighter and timelines can stretch when documentation is not ready.
- Quality beats hype. Strong outcomes, clean documentation, and a clear story of defendable earnings win premium pricing.
- Policy and compliance matter more than ever. Owners who can answer diligence fast and clean protect terms and reduce retrades.
Recommended internal reading:
2) EBITDA Multiples: The Primary Pricing Lens
Most hospice and home health transactions are priced as a multiple of Adjusted EBITDA. Buyers care about earnings quality, sustainability, and risk. Revenue matters, but it usually matters because it supports EBITDA and scale, not because it is the pricing basis.
Highlight: If two agencies have the same revenue but different margins, the higher-margin agency typically commands both a higher dollar value and, often, a higher multiple due to stability and scalability.
3) Home Health Agency EBITDA Multiples (US)
Home health valuations are strong, but buyer diligence often goes deeper on documentation, payer mix, staffing capacity, and policy-driven revenue pressure.
Typical multiple bands
- Small home health agencies: ~3x to 6x EBITDA
- Regional multi-branch agencies: ~6x to 9x EBITDA
- Scaled platforms and premium assets: ~9x to 12x and above (select cases)
Seller note: In 2026, buyers often price risk aggressively. A clean diligence package, strong outcomes, and a clear plan for staffing stability can protect valuation and reduce retrades.
Home Health industry page |
Roadmap to selling a home health business |
More home health valuation posts
Looking for available opportunities?
Healthcare Agencies for Sale Nationwide
4) Home Health Agency Revenue Multiples: How Revenue Ties In (Without Replacing EBITDA)
Revenue multiples are sometimes referenced as shorthand, especially in smaller transactions, early conversations, or asset-style deals. In most healthcare agency transactions, buyers underwrite to adjusted EBITDA and use revenue as a supporting signal of scale, stability, and growth.
- Revenue helps explain scale. Larger revenue often means a bigger, more stable operating engine.
- Margins matter. A high-margin agency can appear expensive on revenue but attractive on EBITDA.
- Growth matters. Strong growth with defendable documentation can expand the multiple.
Practical way to think about it: Revenue supports valuation when it translates to repeatable earnings, not when it is inflated by fragile referral concentration, documentation risk, or staffing instability.
6) What Moves Multiples Up or Down in 2026?
Drivers that increase multiples
- Defensible adjusted EBITDA with clear add-backs and clean financial statements
- Compliance readiness and fast answers to diligence questions
- Quality metrics that support the clinical story
- Referral diversification and stable census or admission trends
- Staffing stability with low turnover and strong leadership bench
- Scale and operational consistency across branches
Drivers that reduce multiples
- Unclear add-backs, messy books, missing backup documentation
- Compliance gaps, survey issues, audit exposure, or weak documentation culture
- Overdependence on owner, a single referral source, or a single market relationship
- Chronic staffing shortages that cap growth or threaten continuity
- Inconsistent margins or unstable census economics
Resources:
Get a Confidential Valuation Conversation
Thinking about selling your home health agency?
If you want a realistic valuation range and a plan to protect terms, we can walk you through what buyers are paying today and what improves pricing in 2026.
Start with valuation resources
|
Contact Vallexa for a confidential consultation
|
Hospice owners
|
Home health owners
Get Deal Flow and Market Intel
Buying home health agencies in the US?
Join our buyer network to receive opportunities that match your criteria. We also help buyers benchmark multiples, diligence risk, and move efficiently from LOI to close.
Join Our Buyer Network
|
View opportunities
|
Talk to our team
7) FAQ: Home Health Valuation Multiples
What is an EBITDA multiple?
An EBITDA multiple is a common valuation method where a buyer values your agency based on a multiple of adjusted EBITDA. The multiple reflects perceived risk, growth, compliance posture, and scale.
What are typical home health EBITDA multiples in 2026?
Many small agencies fall in the ~3x to 6x EBITDA range, while regional multi-branch agencies often price in the ~6x to 9x range. Premium platform assets can command higher multiples in select situations.
Why do two agencies with similar revenue sell for different prices?
Because earnings, risk, and scalability differ. Buyers pay for defensible cash flow, not just top-line revenue. Margin, documentation quality, referral concentration, and staffing stability can dramatically change value.
Do revenue multiples matter in home health deals?
Revenue multiples may appear in early discussions, but most deals are underwritten on adjusted EBITDA. Revenue matters because it supports scale and earnings, not because it replaces EBITDA as the main pricing basis.
How do I increase my multiple before selling?
Improve and document adjusted EBITDA, build a strong diligence package, reduce owner dependency, diversify referrals, and strengthen compliance and quality reporting readiness. Strong presentation and clean documentation protect terms and reduce retrades.
How long does it typically take to sell a home health agency?
Timelines vary. Well-prepared sellers can move faster, while deals can stretch when financials, compliance documentation, or buyer financing slows diligence. Preparing early is a common way to protect value.
Can Vallexa Advisors reference prior deals without naming names?
Yes. We can reference anonymized outcomes and patterns, such as “Texas home health” or “California hospice,” while keeping seller and buyer identities confidential.
More FAQs and guides:
Vallexa Advisors main FAQ |
Hospice valuation guide |
Home health sale process
Explore Vallexa Advisors
Want the full picture, including valuation, exit planning, and current opportunities?
Visit VallexaAdvisors.com for seller resources, buyer opportunities, and healthcare M&A insights.
Go to VallexaAdvisors.com
|
Contact Us
|
Read the step by step sale guide
|
Join the buyer network
Disclosure: This report provides general market education and does not constitute legal, tax, or financial advice. Multiples vary widely based on risk, quality, and market conditions.
Leave a Reply